Kimberly Gentile serves as the Senior Vice President of Clinical Operations at Biohaven Ltd., a biopharmaceutical company focused on developing innovative therapies for neurological and neuropsychiatric diseases. With over two decades of experience in the biopharmaceutical industry, Gentile has established herself as a seasoned leader in clinical operations and drug development. Prior to joining Biohaven, she held key positions at several prominent companies, including Boehringer Ingelheim and Purdue Pharma, where she honed her skills in managing complex clinical trials and regulatory processes. At Biohaven, Gentile plays a pivotal role in overseeing the clinical development of the company's diverse portfolio of drug candidates. Her responsibilities include designing and executing clinical trials, ensuring compliance with regulatory standards, and collaborating with cross-functional teams to advance Biohaven's mission of bringing transformative treatments to patients. Under her leadership, the clinical operations team has made significant strides in advancing several key programs, including those targeting migraine, epilepsy, and rare neurological disorders. Gentile's contributions to the field extend beyond her work at Biohaven. She is an active member of industry associations and has been recognized for her thought leadership in clinical operations and drug development. Her strategic vision and commitment to excellence have been instrumental in driving Biohaven's growth and success, positioning the company as a leader in the development of novel therapies for neurological and neuropsychiatric conditions.